EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis

Nomenclature for 3 stages towards psoriatic arthritis (PsA): people with psoriasis (PsO) at higher risk of PsA, subclinical PsA and clinical PsA

Clinical PsA defined as PsO and associated synovitis; usable as outcome measure in trials of transition from PsO to PsA

Overarching principles address the nature of PsA at onset and the importance of rheumatologist–dermatologist collaboration for prevention/interception of PsA

Arthralgia and imaging abnormalities are key elements of subclinical PsA, potential short-term predictors of PsA and useful items to design PsA interception trials

Traditional risk factors (PsO severity, obesity, nail involvement) may be more long-term predictors and less robust for short-term trials of transition from PsO to PsA